Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Maxus Mining erschließt Wertpotenzial des silberreichen Projekts Quarry mit dem Abschluss der... (IRW Press) +++ MAXUS MINING Aktie +5,31%

OMNICELL Aktie

 >OMNICELL Aktienkurs 
33.8 EUR    (Tradegate)
Ask: 34.2 EUR / 100 Stück
Bid: 33.4 EUR / 100 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
OMNICELL Aktie über LYNX handeln
>OMNICELL Performance
1 Woche: +1,5%
1 Monat: +7,8%
3 Monate: +42,5%
6 Monate: +55,2%
1 Jahr: -1,0%
laufendes Jahr: +6,1%
>OMNICELL Aktie
Name:  OMNICELL INC. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US68213N1090 / 632313
Symbol/ Ticker:  OC9 (Frankfurt) / OMCL (NASDAQ)
Kürzel:  FRA:OC9, ETR:OC9, OC9:GR, NASDAQ:OMCL
Index:  -
Webseite:  https://www.omnicell.com/
Profil:  Omnicell Inc. operates as a provider of medication..
>Volltext..
Marktkapitalisierung:  1850.01 Mio. EUR
Unternehmenswert:  1834.14 Mio. EUR
Umsatz:  996.96 Mio. EUR
EBITDA:  89.37 Mio. EUR
Nettogewinn:  16.86 Mio. EUR
Gewinn je Aktie:  0.37 EUR
Schulden:  175.04 Mio. EUR
Liquide Mittel:  190.85 Mio. EUR
Operativer Cashflow:  129.74 Mio. EUR
Bargeldquote:  0.49
Umsatzwachstum:  5.01%
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 304.689 USD.
Suchwörter:  OMNICELL
Letzte Datenerhebung:  05.02.26
>OMNICELL Kennzahlen
Aktien/ Unternehmen:
Aktien: 44.88 Mio. St.
Frei handelbar: 97.01%
Rückkaufquote: 1.69%
Mitarbeiter: 3670
Umsatz/Mitarb.: 0.26 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 22.74%
Bewertung:
KGV: 106.78
KGV lG: 26.55
KUV: 1.93
KBV: 1.67
PEG-Ratio: -
EV/EBITDA: 20.52
Rentabilität:
Bruttomarge: 43.82%
Gewinnmarge: 1.69%
Operative Marge: 1.57%
Managementeffizenz:
Gesamtkaprendite: 0.94%
Eigenkaprendite: 1.62%
>OMNICELL Peer Group
Gesundheit
 
05.02.26 - 12:42
Omnicell reports mixed Q4 results; initiates Q1 and FY26 outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.02.26 - 12:33
Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results (Business Wire)
 
Omnicell delivers solid fourth quarter 2025 financial results Announces major step toward autonomous medication management with the launch of its next generation dispensing system, Titan XT, at the American Society of Health-System Pharmacists (ASHP) 2025 Midyear Clinical Meeting & ExhibitionFORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading healthcare technology provider focused on empowering autonomous medication management, today announced results for its fiscal year and fourth quarter ended December 31, 2025. “We finished 2025 with solid fourth quarter financial results, delivering full year 2025 total revenues, product bookings and annual recurring revenues ('ARR') all above the mid-point of our previously issued guidance ranges,” stated Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “As we look ahead, we are focused on delivering long-term, s...
04.02.26 - 20:03
Omnicell upgraded at BofA on buying opportunity ahead of Q4 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.02.26 - 16:01
BofA upgrades Omnicell as new product cycle to drives revenue revisions (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
04.02.26 - 15:42
Omnicell Q4 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.01.26 - 17:30
Earnings Preview: Omnicell (OMCL) Q4 Earnings Expected to Decline (Zacks)
 
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
22.01.26 - 11:30
Zacks Industry Outlook Highlights Doximity, 10x Genomics and Omnicell (Zacks)
 
Doximity, 10x Genomics and Omnicell stand out in the Medical Info Systems sector, leveraging AI, telehealth, and workflow innovations for growth....
13.01.26 - 19:45
All You Need to Know About Omnicell (OMCL) Rating Upgrade to Buy (Zacks)
 
Omnicell (OMCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
13.01.26 - 14:03
Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 (Business Wire)
 
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the fourth quarter and full year 2025, before market open on Thursday, February 5, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 4203777. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About Omnicell Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous me...
13.01.26 - 02:01
Insiderhandel: EVP&CHIEF LEGAL/ADMIN OFFICER verkauft Aktien von Omnicell im Wert von 304689 USD (Insiderkauf)
 
Manley, Corey J. - Vorstand - Tag der Transaktion: 2026-01-08...
08.01.26 - 19:36
Omnicell upgraded at KeyBanc on Titan XT and competitive conversions (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.01.26 - 19:21
Omnicell looks at long-term growth tied to cabinet replacement cycle (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
05.01.26 - 22:00
Omnicell Executive Trims Holdings in $244,000 Sale as Stock Trades Near 2025 Highs (Fool)
 
The stock has rallied significantly from its 52-week low of $22.66 in May....
29.12.25 - 17:30
Implied Volatility Surging for Omnicell Stock Options (Zacks)
 
Investors need to pay close attention to Omnicell stock based on the movements in the options market lately....
18.12.25 - 00:01
Insiderhandel: EVP&CHIEF LEGAL/ADMIN OFFICER verkauft Aktien von Omnicell im Wert von 12037 USD (Insiderkauf)
 
Manley, Corey J. - Vorstand - Tag der Transaktion: 2025-12-16...
08.12.25 - 19:01
Omnicell-Aktie legt nach Vorstellung eines neuen Medikamenten-Management-Systems zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.12.25 - 02:01
Insiderhandel: EVP&CHIEF LEGAL/ADMIN OFFICER verkauft Aktien von Omnicell im Wert von 243629 USD (Insiderkauf)
 
Manley, Corey J. - Vorstand - Tag der Transaktion: 2025-12-03...
05.12.25 - 16:00
Reasons to Add Omnicell Stock to Your Portfolio Right Now (Zacks)
 
OMCL's expanding SaaS pipeline, global push and solid solvency highlight growth potential despite rising competition....
04.12.25 - 02:02
Insiderhandel: CHAIRMAN, PRESIDENT AND CEO verkauft Aktien von Omnicell im Wert von 1016093 USD (Insiderkauf)
 
Lipps, Randall A. - Vorstand - Tag der Transaktion: 2025-12-01...
27.11.25 - 17:30
Wall Street Analysts Think Omnicell (OMCL) Could Surge 30.93%: Read This Before Placing a Bet (Zacks)
 
The consensus price target hints at a 30.9% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Angefressenheit nimmt stark zu. Jeder kocht sein eigenes Süppchen. - Ernst Ferstl
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!